Bosulif® (bosutinib)
for Leukemia

Bosulif (bosutinib) is a kinase inhibitor approved for treating chronic myelogenous leukemia (CML) in adults and some children (≥1 year old). It targets BCR-ABL kinase, a protein driving leukemia cell growth, and also inhibits Src family kinases (Src, Lyn, Hck). Bosulif also treats Philadelphia chromosome-positive (Ph+) CML in chronic, accelerated, or blast phases, particularly after other treatments fail or cause intolerance.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Leukemia